
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics is experiencing a strong uptake in prescriptions of their product ZELSUVMI for the treatment of molluscum contagiosum, and with the recent addition of new territories for commercialization, the company now covers over half of MC claims. The commercial expansion and successful launch of this first-in-class at-home treatment option positions Pelthos for significant revenue growth in the future, making it an attractive investment opportunity. The company also has a strong pipeline, including a novel NaV blocker platform targeting pain management, which could provide additional revenue opportunities in the future.
Bears say
Pelthos Therapeutics is facing challenges in their commercial operations segment, with limited traction in their ZELSUVMI product and minimal sales growth. Despite having a large and underserved market in MC cases, the lack of treatment options results in low treatment penetration and creates uncertainty for the success of Pelthos' existing and expanding pipeline. Furthermore, with no expectations for 2026 guidance and continued concerns about current trends, the company's commercial outlook is uncertain and may cause further negative sentiment among investors and analysts.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares